THC Use Alone May Not Derail Methadone Treatment Access

During the Covid-19 pandemic, emergency regulations allowed opioid treatment programs to relax certain restrictions — including rules about take-home methadone. This study took advantage of that window to examine a pressing real-world question: does ongoing THC use alone disqualify patients from maintaining access to take-home methadone? Researchers followed 33 patients at a single Midwestern opioid treatment program and tracked how long they remained eligible for weekly take-home doses despite continued THC use.

Using Kaplan-Meier survival analysis, the study found that the majority of patients who continued using THC remained eligible for take-home methadone for up to 10 months. This is a significant finding given that, historically, any positive drug screen — including for cannabis — could result in patients losing take-home privileges and being required to attend the clinic daily. The cohort was notably stable: most participants were employed, insured, and housed, though statistical tests showed these socioeconomic factors did not reach significance as individual predictors of eligibility.

The broader implication is that THC use alone may be less critical a barrier to take-home methadone access than current policies often treat it. The authors argue this warrants deeper investigation, especially as cannabis becomes more widely legalized and opioid treatment programs reassess outdated policies. For the millions of Americans in opioid treatment, loosening THC-related restrictions could meaningfully reduce daily clinic burdens without compromising treatment outcomes.